Press Releases
Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other ocular diseases caused by oxidative stress, today announced that the first patients have been implanted in the final cohort of the Phase 1/2 clinical trial evaluating NPI-002 for delayed cataract progression in patients undergoing vitrectomy. An independent Data Safety Monitoring Board (DSMB) recommended proceeding with the final cohort after a positive safety review, which was subsequently approved by the overseeing Human Research Ethics Committee. Read more...
Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel treatments for retinitis pigmentosa, cataract, and other diseases caused by oxidative stress, today announced the appointment of Emmett T. Cunningham, Jr., M.D., Ph.D., MPH, to its board of directors. Dr. Cunningham is currently a Senior Partner at HealthQuest Capital Management and co-founder and Executive Chairman of Eyconis, Inc., a spinout of Ascendis Pharma created to develop, manufacture, and commercialize TransCon ophthalmology assets globally. Read more...
Arctic Therapeutics ehf, an Icelandic drug development company and partner Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by oxidative stress, today announced approval by the European Medicines Agency (EMA) for initiation of the first clinical trial evaluating AT-001 (Nacuity’s NPI-001) for the treatment of Hereditary Cystatin C Amyloid Angiopathy (HCCAA) in Iceland. Read more...
Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by oxidative stress, today announced the expansion of its business advisory board with the appointment of Daniel Feller. Mr Feller is a co-founder of Genetic Cures Australia, which supports the growth of medical research on gene-based approaches and emerging therapies for inherited rare diseases in Australia. Read more...
Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by oxidative stress, today announced that a clinical trial site has been added to its Phase 1/2 clinical trial evaluating NPI-002, a proprietary antioxidant molecule delivered via a sustained release intravitreal implant, for the delay of cataract progression in patients undergoing vitrectomy. Read more...
Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by oxidative stress, today announced that target enrollment of 48 patients has been reached in the SLO-RP Phase 1/2 clinical trial of NPI-001 tablets in patients with retinitis pigmentosa (RP) associated with Usher syndrome (USH). Read more...
Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts, and other ocular diseases caused by oxidative stress, today announced the appointment of Russell Kelley, Ph.D., MBA, to its board of directors. Dr. Kelley currently serves as managing director of the Retinal Degeneration (RD) Fund, the venture arm of Foundation Fighting Blindness and a significant investor of Nacuity. Read more...
Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by oxidative stress, and Arctic Therapeutics International, a precision-based drug development and diagnostic testing company using genetic and genealogy information to guide therapeutic development, today announced the companies have entered into an exclusive licensing agreement and strategic partnership for the development and commercialization of NPI-001 in Iceland for the treatment of hereditary cystatin C amyloid angiopathy (HCCAA). Read more...
Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other ocular diseases caused by oxidative stress, today announced the closing of a $16.5 million Series B financing led by Foundation Fighting Blindness and its venture arm RD Fund. Additional existing investors also participated in the round. Maxim Merchant Capital, a division of Maxim Group LLC, served as sole placement agent for the financing. Read more...
Nacuity Pharmaceuticals, Inc. (Nacuity) today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of Nancy Holekamp, M.D., and Richard L. Lindstrom, M.D. Read more...
Nacuity Pharmaceuticals, Inc. (Nacuity) today announced the initiation of a Phase 1/2 study of NPI-001 tablets in patients with retinitis pigmentosa (RP) associated with Usher syndrome (USH). The study, named SLO-RP, is designed to demonstrate greater retinal sensitivity in RP/USH patients treated with NPI-001 Tablets versus placebo. Read more...
Nacuity Pharmaceuticals, Inc. (Nacuity) announces that it has entered into an agreement with Johns Hopkins University (JHU) providing Nacuity with an exclusive worldwide license to the intellectual property (IP) underlying certain U.S. and foreign patent applications that Nacuity has filed in collaboration with the Johns Hopkins Wilmer Eye Institute. Read more...
